CASE REPORT

Neuromyelitis optica spectrum disease coexisting with subacute combined degeneration: a case report

Yixuan Zeng, Runtao Bai, Yanxia Zhou and Lijie Ren*

Abstract

Background: Subacute combined degeneration (SCD) is a demyelinating disease characterized by vitamin B12 deficiency related segmental degeneration of the dorsal or lateral columns of the spinal cord. However, few cases have been reported as a comorbidity of SCD and neuromyelitis optica spectrum disease (NMOSD).

Case presentation: Herein, we describe a female patient (61-year-old) who had sensory deficits, paresthesia, and weakness of the distal extremities for over 2 months. She then received an initial diagnosis of SCD with typical inverted “V-sigh” hyperintensities over the posterior aspect of the spinal cord in magnetic resonance imaging (MRI - T2-weighted imaging), as well as megaloblastic anaemia in blood examinations. From the past history, there was no evidence of a dietary deficiency or gastric abnormalities. However, traditional treatment with vitamin B12 supplementation was ineffective. Hence, a demyelinating antibody examination showed that she had antibodies targeting aquaporin 4 (AQP4) in both the cerebrospinal fluid and serum, leading to the diagnosis of NMOSD. Her clinical symptoms were obviously improved after treatment with intravenous glucocorticoids.

Conclusion: People who have nutritional deficiency or altered gastrointestinal function are more likely to develop SCD. This case raises the awareness that the poor therapeutic effects of simple vitamin B12 supplementation could be explained by immunoreactions against AQP4. A better recognition will be of great importance for the correct diagnosis of the comorbidity, as well as for essential treatment and even a better prognosis.

Keywords: Subacute combined degeneration, Neuromyelitis optica spectrum disorders, Vitamin B12 deficiency, Aquaporin 4, Magnetic resonance imaging
glucocorticoids in this patient, as well as the importance of antibody testing in SCD patients.

Case presentation

A 61-year-old woman presented with numbness and weakness in all of her extremities for over 2 months. She then went to the community clinic and received treatment of oral vitamin B12 (1 mg per day) with the guidance of community doctors. She felt slight improvement of the numbness when first got oral vitamin B12 treatment for about a week. However, after the orally treatment of vitamin B12 for one month, her symptoms worsened over time and interfered with her daily life. And then she was admitted to department of neurology in our hospital. The patient had Hashimoto’s thyroiditis and hypertension, as well as good compliance with the hypotensor. In addition, she had a good dietary intake with a negative history of alcohol, cigarettes, illicit drugs, or gastrointestinal surgery. She was conscious and fluent in speech when she arrived at our clinic. A neurological examination showed no abnormalities in cranial nerves. A marked increase in the deep tendon reflexes, mild weakness in the limbs (grade 4), and impaired vibration sensation and joint position were detected on the neurological examination. Neither Babinski’s sign nor Romberg’s sign were detected at that time. The scores of the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were both 21 out of 30. Moreover, macrocytic anaemia was demonstrated by the laboratory tests. There was a decrease in red blood cells (RBCs) \((2.47 \times 10^{12}/L, \text{reference range: } 4.30–5.80 \times 10^{12}/L)\) and haemoglobin (Hb) \((106 \text{g/L, reference range: } 130–175 \text{g/L})\), which were accompanied by an increase in MHC \((42 \text{pg, reference range: } 27–34 \text{pg})\), MCHC \((360 \text{g/L, reference range: } 320–360 \text{g/L})\), and MCV \((116.7 \text{fl, reference range: } 82–100 \text{fl})\). Furthermore, a lower vitamin B12 \((147 \text{pmol/L, reference range: } 211–911 \text{pmol/L})\) level was detected even after supplementary treatment with vitamin B12. The level of serum homocysteine (Hcy) \((31.6 \text{μmol/L, reference range: } 4–15.4 \text{μmol/L})\), an indicator of the function of vitamin B12 deficiency at the cellular level, was out of the normal range.

The cerebrospinal fluid (CSF) showed normal leukocyte, chloride, glucose, and protein results. Anti-intrinsic factor antibody and tumour markers (CEA, AFP, CA125, CA724, CA19–9, and CA15–3) were all unremarkable. Nerve conduction studies and electromyogram (EMG) were normal. In spinal cord T2-weighted MRI, long segmental hyperintensities involving the posterior columns of the spinal cord were observed in sagittal images (C2 to C6) (Fig. 1a), whereas a typical inverted “V-sign” was observed in axial images (Fig. 1b). No abnormality was found in the brain MRI scan. She was initially diagnosed with SCD for unknown reasons. As she was benefits from

---

**Fig. 1** Spinal cord MRI. a Sagittal T2-weighted imaging showed long segmental hyperintensities from C2 to C6 of the spinal cord. b Inverted “V-sign” hyperintensity on axial T2-weighted imaging within the dorsal cervical spinal cord. c After 3 months of continuous immune therapy, there was a decreased signal on axial T2-weighted imaging, both horizontally and longitudinally. d After 3 months of continuous immune therapy, the inverted “V-sign” hyperintensity faded on axial T2-weighted imaging.
oral vitamin B12 supplementation at the very beginning, a high dose of supplementary intramuscular vitamin B12 injections (1.5 mg per day) was given immediately after she came to our department. And at the same time, a neuromyelitis optica (NMO) antibody test was then performed, as there was a longitudinally extended lesion on the sagittal MRI as well as the poor curative effect of vitamin B12 supplementation alone. The results showed that antibody targeting aquaporin 4 (AQP4) was positive in both the serum (12.86 u/ml) and in the CSF (7.98 u/ml), and a myelin-oligodendrocyte glycoprotein (MOG) antibody test was negative. She was then diagnosed with NMOSD coexisting with SCD.

Subsequently, she received intravenous methylprednisolone treatment (500 mg/day for 3 days, 250 mg/day for 3 days, 120 mg/day for 3 days). Symptoms of weakness were improved via the intravenous methylprednisolone treatment. After intravenous methylprednisolone, she continued the oral prednisolone treatment for 6 months. The course of intramuscular vitamin B12 injections for 1 month with a following daily oral vitamin B12 supplementation treatment (1 mg per day) for 6 months. 3 months after discharged, except for slight numbness in the fingers, symptoms of paraesthesia and limb weakness had resolved. Additionally, her anaemia improved (RBC 3.48 $\times 10^{12}$/L and Hb 127.0 g/L), and the vitamin B12 level in serum increased to more than the maximum measurable value. Signal abnormalities observed in the MRI also improved, both horizontally and longitudinally (Fig. 1c, d). During her next 6-month follow-up, her symptoms were completely relieved. In addition, no tumour signs were discovered during the follow-up period.

**Discussion and conclusions**

SCD is an uncommon type of myelopathy. NMOSD is also an uncommon antibody-mediated disease of the central nervous system (CNS). Here we reported a rare clinical case of simultaneous NMOSD and SCD with a subacute onset of numbness and weakness in all of her extremities [1]. A typical imaging finding of SCD is an increased signal intensity (inverted “V” sign) in the dorsal columns of the cervical cord in MRI T2-weighted imaging [2]. One of the specific presentations of NMOSD is longitudinally extensive transverse (but not selective) myelitis [3]. The relationship between SCD and NMOSD remains unclear.

A retrospective analysis of aquaporin-4 antibody-positive NMO patients by the Neurosciences Group at Oxford University found that 46.2% of the confirmed patients had low vitamin B12 levels (mean: 150 pmol/L; standard: 300 pmol/L) without positive anti-intrinsic factor antibody [4]. This finding can be explained by the fact that the cell membranes of gastric parietal cells are also rich in AQP4 expression; thus, gastric parietal cells may also be damaged due to the immune response. As a result, the low level of vitamin B12 in NMOSD patients may be caused by damage to the humorall immune response to gastric parietal cells. One hypothesis is that SCD caused by vitamin B12 deficiency may be one of the clinical manifestations of NMOSD. The systemic immune response associated with AQP4 leads to a diversity of clinical symptoms. Therefore, NMOSD always coexists with other humorall autoimmune diseases, such as connective tissue disease, myasthenia gravis, or celiac disease [5, 6].

Moreover, as an intermediate of cobalamin metabolism, elevation of Hcy can be used to confirm B12 deficiency [7]. Hcy should be measured in patients with suspected clinical B12 deficiency, especially when serum B12 levels are either normal, borderline, or accompanied by macrocytic anaemia [8]. High Hcy levels can increase the production of reactive oxygen species (ROS) to induce oxidative stress and stimulate the N-methyl-D-aspartate (NMDA) receptor to promote excitotoxicity [9]. Hence, Hcy will lead to neuronal damage, as the nervous system is particularly sensitive. Serum Hcy levels can also be used as an independent predictor of recurrence and poor prognosis for NMOSD patients [10]. For most patients with SCD or NMOSD, MRI results are always delayed behind the clinical presentation; therefore, long-term follow-up is needed.

In conclusion, even if it is easy to diagnose SCD by detecting vitamin B12 levels and by utilizing spinal cord MRI, it is usually difficult to determine the real pathology of vitamin B12 deficiency. Nutritional supplementation alone may lead to the delay of effective treatment and the aggravation of SCD. Therefore, AQP4 antibody examination is suggested for SCD patients with no obvious cause and poor effects of routine treatment. Moreover, immunotherapy is necessary in AQP4-positive cases [11, 12]. Finally, a long-term prognosis is as important as the determination of the underlying aetiology for SCD patients.

**Abbreviations**

AQP4: Aquaporin 4; CNS: Central nervous system; CSF: Cerebrospinal fluid; Hb: Hemoglobin; Hcy: Homocysteine; MMSE: Mini-Mental State Examination (MMSE); MoCA: Montreal Cognitive Assessment (MoCA); NMDA: N-methyl-D-aspartate; NMO: Neuromyelitis optica; NMOSD: Neuromyelitis optica spectrum disorders; MOG: Myelin-oligodendrocyte glycoprotein; MRI: Magnetic resonance imaging; RBC: Red blood cell; ROS: Reactive oxygen species; SCD: Subacute combined degeneration.

**Acknowledgments**

The authors would like to thank the patient and his family for their participation and help.
Authors' contributions
YanXZ: conceptualization and design of the study. YiXZ: interpretation of data, drafting and revising the manuscript. RTB and LJR: critical revision of the manuscript for important intellectual content, study supervision. All authors have read and approved the manuscript.

Funding
This research was supported by grants from Shenzhen second people’s hospital clinical research project (No.20203357027). The design of the study, and interpretation of data and in writing the manuscript were all supported by this funding.

Availability of data and materials
Data has not been made accessible in the interest of protecting patient’s privacy.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent for publication was obtained from the patient.

Competing interests
The authors declare that they have no competing interests.

Received: 6 April 2022 Accepted: 2 September 2022
Published online: 04 October 2022

References
1. Ishii N, Mochizuki H, Takahashi T, Shiomi K, Nakazato M. A case of simultaneous neuromyelitis optica spectrum disorder and subacute combined degeneration. Neurol Sci. 2013;34(10):1819–21. https://doi.org/10.1007/s10072-013-1301-4.
2. Gao H, et al. Clinical and MRI differences between patients with subacute combined degeneration of the spinal cord related vs. unrelated to recreational nitrous oxide use: a retrospective study. Front Neurol. 2021;12:626174.
3. Wingerchuk DM, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89.
4. Jarius S, et al. Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol. 2012;259(12):2743–5.
5. Zhang B, et al. Neuromyelitis optica spectrum disorders without and with autoimmune diseases. BMC Neurol. 2014;14(1):162.
6. Shahmohammadi S, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum disorders: a literature review. Mult Scler Relat Disord. 2019;27:350–63.
7. Skovierova H, et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int J Mol Sci. 2016;17(10):1733.
8. Bi Z, et al. Correlation between anemia and clinical severity in subacute combined degeneration patients. J Clin Neurosci. 2020;80:11–5.
9. Temple C, Zane Horowitz B. Nitrous oxide abuse induced subacute combined degeneration despite patient initiated B12 supplementation. Clin Toxicol (Phila). 2022;60:1–4.
10. Zhang J, et al. Serum homocysteine level is a predictor of relapse and prognosis in patients with first-attack Neuromyelitis Optica Spectrum disorders. Front Neurol. 2021;12:667651.
11. Romeo AR, Segal BM. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol. 2019;31(3):250–5.
12. Selmaï K, Selmaï I. Novel emerging treatments for NMOSD. Neurol Neurochir Pol. 2019;53(5):317–26.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.